EP1448588A4 - Psma antibodies and protein multimers - Google Patents

Psma antibodies and protein multimers

Info

Publication number
EP1448588A4
EP1448588A4 EP02802198A EP02802198A EP1448588A4 EP 1448588 A4 EP1448588 A4 EP 1448588A4 EP 02802198 A EP02802198 A EP 02802198A EP 02802198 A EP02802198 A EP 02802198A EP 1448588 A4 EP1448588 A4 EP 1448588A4
Authority
EP
European Patent Office
Prior art keywords
psma antibodies
protein multimers
multimers
protein
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02802198A
Other languages
German (de)
French (fr)
Other versions
EP1448588A2 (en
Inventor
Paul J Maddon
Gerald P Donovan
William C Olson
Norbert Schuelke
Jason Gardner
Dangshe Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PSMA Development Co LLC
Original Assignee
PSMA Development Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27407041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1448588(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PSMA Development Co LLC filed Critical PSMA Development Co LLC
Priority to EP10184938.8A priority Critical patent/EP2363404B8/en
Priority to EP10184957.8A priority patent/EP2360169B1/en
Priority to EP16187305.4A priority patent/EP3184539A3/en
Publication of EP1448588A2 publication Critical patent/EP1448588A2/en
Publication of EP1448588A4 publication Critical patent/EP1448588A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
EP02802198A 2001-10-23 2002-10-23 Psma antibodies and protein multimers Withdrawn EP1448588A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10184938.8A EP2363404B8 (en) 2001-10-23 2002-10-23 PSMA antibodies
EP10184957.8A EP2360169B1 (en) 2001-10-23 2002-10-23 PSMA antibodies
EP16187305.4A EP3184539A3 (en) 2001-10-23 2002-10-23 Psma antibodies

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33521501P 2001-10-23 2001-10-23
US335215P 2001-10-23
US36274702P 2002-03-07 2002-03-07
US362747P 2002-03-07
US41261802P 2002-09-20 2002-09-20
US412618P 2002-09-20
PCT/US2002/033944 WO2003034903A2 (en) 2001-10-23 2002-10-23 Psma antibodies and protein multimers

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP10184938.8A Division EP2363404B8 (en) 2001-10-23 2002-10-23 PSMA antibodies
EP16187305.4A Division EP3184539A3 (en) 2001-10-23 2002-10-23 Psma antibodies
EP10184957.8A Division EP2360169B1 (en) 2001-10-23 2002-10-23 PSMA antibodies

Publications (2)

Publication Number Publication Date
EP1448588A2 EP1448588A2 (en) 2004-08-25
EP1448588A4 true EP1448588A4 (en) 2006-10-25

Family

ID=27407041

Family Applications (4)

Application Number Title Priority Date Filing Date
EP02802198A Withdrawn EP1448588A4 (en) 2001-10-23 2002-10-23 Psma antibodies and protein multimers
EP10184957.8A Revoked EP2360169B1 (en) 2001-10-23 2002-10-23 PSMA antibodies
EP16187305.4A Withdrawn EP3184539A3 (en) 2001-10-23 2002-10-23 Psma antibodies
EP10184938.8A Expired - Lifetime EP2363404B8 (en) 2001-10-23 2002-10-23 PSMA antibodies

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP10184957.8A Revoked EP2360169B1 (en) 2001-10-23 2002-10-23 PSMA antibodies
EP16187305.4A Withdrawn EP3184539A3 (en) 2001-10-23 2002-10-23 Psma antibodies
EP10184938.8A Expired - Lifetime EP2363404B8 (en) 2001-10-23 2002-10-23 PSMA antibodies

Country Status (7)

Country Link
US (2) US7850971B2 (en)
EP (4) EP1448588A4 (en)
JP (3) JP5355839B2 (en)
AU (1) AU2002356844C1 (en)
CA (1) CA2464239C (en)
ES (2) ES2606537T3 (en)
WO (1) WO2003034903A2 (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
MXPA04007262A (en) * 2002-01-28 2004-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen (psma).
PT1545613E (en) 2002-07-31 2011-09-27 Seattle Genetics Inc Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2514419A1 (en) * 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
AU2003903501A0 (en) * 2003-07-07 2003-07-24 Commonwealth Scientific And Industrial Research Organisation A method of forming a reflective authentication device
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
JP4560314B2 (en) * 2004-03-17 2010-10-13 ジェイファーマ株式会社 Method for detecting cancer with neutral amino acid transporter and kit for the same
CA2606138A1 (en) * 2004-04-19 2005-10-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
PL1833506T3 (en) * 2004-12-29 2016-01-29 Mannkind Corp Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US20090297438A1 (en) * 2005-02-18 2009-12-03 Haichun Huang Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)
DK1874821T3 (en) 2005-04-26 2013-07-08 Trion Pharma Gmbh Combination of antibodies with glycocorticoids to treat cancer
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CA2612762C (en) * 2005-06-20 2013-12-10 Psma Development Company, Llc Psma antibody-drug conjugates
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
EP1979410B1 (en) * 2005-12-29 2012-08-22 Life Technologies Corporation Compositions and methods for improving resolution of biomolecules separated on polyacrylamide gels
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
ES2381788T3 (en) 2007-07-16 2012-05-31 Genentech, Inc. Anti-CD79b and immunoconjugate antibodies and methods of use
EP3714906A1 (en) * 2007-10-03 2020-09-30 Cornell University Treatment of proliferative disorders using radiolabelled antibodies to psma
UA106586C2 (en) 2008-01-31 2014-09-25 Дженентек, Інк. Anti-cd79b antibodies and imunokonugate and methods for their use
CA2718942A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
EP2352763B2 (en) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
WO2010096486A1 (en) * 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
CN104619349B (en) 2012-06-07 2018-07-10 Ambrx公司 Prostate-specific membrane antigen antibody drug conjugate
JP2015521602A (en) 2012-06-14 2015-07-30 アンブルックス, インコーポレイテッドAmbrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
WO2013192242A2 (en) * 2012-06-18 2013-12-27 University Of Southern California Cell surface marker and methods of use thereof
HUE045435T2 (en) 2012-10-12 2019-12-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
JP6908964B2 (en) 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Combination therapy with PSMA ligand conjugate
WO2015073896A2 (en) 2013-11-15 2015-05-21 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
KR20220044377A (en) 2014-04-03 2022-04-07 아이쥐엠 바이오사이언스 인코포레이티드 Modified j-chain
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CN107849148B (en) 2015-05-21 2023-09-19 哈普恩治疗公司 Trispecific binding proteins and methods of use
MX2017017172A (en) 2015-06-22 2018-02-23 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups.
JOP20160154B1 (en) * 2015-07-31 2021-08-17 Regeneron Pharma Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
ES2819870T3 (en) 2015-09-30 2021-04-19 Igm Biosciences Inc Modified J-chain binding molecules
CN108463245A (en) 2015-09-30 2018-08-28 Igm生物科学有限公司 The binding molecule of J chains with modification
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3402824A1 (en) 2016-01-12 2018-11-21 Crescendo Biologics Limited Therapeutic molecules
KR20180123047A (en) 2016-03-24 2018-11-14 바이엘 파마 악티엔게젤샤프트 Prodrugs of cytotoxic activators with enzymatically cleavable groups
US11414497B2 (en) 2016-04-13 2022-08-16 Orimabs Ltd. Anti-PSMA antibodies and use thereof
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN116987189A (en) 2016-05-20 2023-11-03 哈普恩治疗公司 Single chain variable fragment CD3 binding proteins
CN117534764A (en) * 2016-06-06 2024-02-09 阿布泽纳(英国)有限公司 Antibodies, uses thereof and conjugates thereof
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
JP7215997B2 (en) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． Trispecific proteins targeting prostate specific membrane antigen (PSMA) and methods of use
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018114798A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3558388A1 (en) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) having enzymatically cleavable groups
EP3558387B1 (en) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
EP3565841A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
CA3054248A1 (en) 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
SG10202109376YA (en) 2017-02-28 2021-10-28 Immunogen Inc Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
JP7284707B2 (en) 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド Engineered Cells Expressing Prostate-Specific Membrane Antigen (PSMA) or Modified Forms Thereof and Related Methods
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
EP3621648A4 (en) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CN111630070A (en) 2017-10-13 2020-09-04 哈普恩治疗公司 Trispecific proteins and methods of use
EA202090739A1 (en) 2017-10-13 2020-09-07 Харпун Терапьютикс, Инк. PROTEINS BINDING ANTIGEN OF MATURING B-CELLS
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
EP3762410A4 (en) 2018-03-06 2022-04-06 The Trustees of the University of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
MA52186A (en) 2018-03-26 2021-02-17 Amgen Inc TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20220185910A1 (en) * 2018-06-18 2022-06-16 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
EP3927374A1 (en) 2019-02-21 2021-12-29 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
EP3927339A1 (en) 2019-02-22 2021-12-29 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
US11180563B2 (en) 2020-02-21 2021-11-23 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
EP4130006A4 (en) 2020-03-25 2024-01-17 Jiangsu Hengrui Pharmaceuticals Co Ltd Anti-psma antibody-exatecan analogue conjugate and medical use thereof
IL297423A (en) * 2020-04-24 2022-12-01 Radiomedix Inc Composition, kit and method for diagnosis and treatment of prostate cancer
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP2023548767A (en) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド Relative unpaired glycans in antibody production methods
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
JP2023552812A (en) 2020-12-09 2023-12-19 ジャナックス セラピューティクス，インク． Compositions and methods related to tumor-activating antibodies targeting PSMA and effector cell antigens
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AR126089A1 (en) 2021-06-07 2023-09-13 Amgen Inc USE OF FUCOSIDASE TO CONTROL THE LEVEL OF AFFUCOSYLATION OF GLUCOSYLATED PROTEINS
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023222557A1 (en) * 2022-05-17 2023-11-23 Bayer Aktiengesellschaft Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations
EP4279092A1 (en) * 2022-05-17 2023-11-22 Bayer AG Radiopharmaceutical complexes targeting prostate-specific membrane antigen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DE3432714A1 (en) 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg TUMOR THERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF
US5153118A (en) 1985-12-17 1992-10-06 Eastern Virginia Medical Authority Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
US5055559A (en) 1986-02-20 1991-10-08 Oncogen Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
JPH0695949B2 (en) 1987-09-08 1994-11-30 工業技術院長 Human IgG1 type monoclonal antibody
US5688657A (en) 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
FR2635008B1 (en) 1988-08-05 1990-11-16 Sanofi Sa ACTIVATOR FOR THE SPECIFIC PRODUCTIVITY OF RECOMBINANT ANIMAL CELLS BASED ON POLYVINYLPYRROLIDONE AND DEFINED CULTURE MEDIUM CONTAINING THE SAME
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5281699A (en) 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2171410T3 (en) 1991-11-26 2002-09-16 Jenner Technologies ANTITUMOR VACCINES.
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5756825A (en) 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
EP1757694A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5925362A (en) 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
WO1996026272A1 (en) 1995-02-24 1996-08-29 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6224870B1 (en) 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US20040253246A1 (en) 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DK0914155T3 (en) * 1996-03-25 2006-06-26 Medarex Inc Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20010036928A1 (en) 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
IL127605A0 (en) 1996-06-17 1999-10-28 Guilford Pharm Inc Methods of cancer treatment using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
EP0959893A4 (en) 1996-12-10 2004-11-10 Sloan Kettering Institutefor C Stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US20020155093A1 (en) 1997-02-18 2002-10-24 Houghton Alan N. Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
EP0994707A4 (en) 1997-05-27 2001-11-14 Guilford Pharm Inc Inhibitors of naaladase enzyme activity
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6372955B1 (en) * 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
FR2776702B1 (en) 1998-03-24 2000-05-05 Elf Exploration Prod METHOD FOR CONDUCTING A HYDROCARBON PRODUCTION FACILITY
US6200765B1 (en) 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
JP2000080100A (en) * 1998-06-17 2000-03-21 Japan Tobacco Inc Human monoclonal antibody against parathyroid hormone-related protein
ES2251204T3 (en) 1998-07-06 2006-04-16 Mgi Gp, Inc. NAALADASA INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS.
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
ATE465266T1 (en) 1998-12-31 2010-05-15 Novartis Vaccines & Diagnostic COMPOSITIONS AND METHODS FOR PACKAGING ALPAVIRUS VECTORS
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
DE60039032D1 (en) 1999-03-01 2008-07-10 Commw Scient Ind Res Org REGULATORY CONSTRUCTS, THE INTRON 3 OF THE PR
US6897062B1 (en) 1999-04-09 2005-05-24 Sloan-Kettering Institute For Cancer Research DNA encoding the prostate-specific membrane antigen-like gene and uses thereof
EP1177207A4 (en) 1999-04-09 2003-06-04 Sloan Kettering Inst Cancer Dna encoding the prostate-specific membrane antigen-like gene and uses thereof
EP1553414A1 (en) 1999-04-13 2005-07-13 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
JP2002540814A (en) 1999-04-13 2002-12-03 ノースウエスト バイオセラピューティクス，インコーポレイティド Methods for diagnosis and treatment of metastatic prostate tumor
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
EP1512755A3 (en) 1999-06-10 2007-11-21 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
JP2003535024A (en) 1999-06-29 2003-11-25 エピミューン インコーポレイテッド HLA binding peptides and uses thereof
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
FR2797743B1 (en) 1999-08-23 2003-08-08 Urogene PROSTATIC CELL LINE AND ITS USE FOR OBTAINING AN ESTABLISHED PROSTATIC TUMOR IN ANIMALS
WO2001019956A2 (en) 1999-09-13 2001-03-22 Bander Neil H A method for isolation of prostatic epithelial cells from semen
WO2001045728A2 (en) 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
AU2001242190A1 (en) 2000-03-31 2001-10-15 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
NZ534864A (en) 2000-05-08 2006-04-28 Celldex Therapeutics Inc Human monoclonal antibodies to dentritic cells
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
IL152655A0 (en) 2000-05-12 2003-06-24 Northwest Biotherapeutics Inc Method to increase class i presentation of exogenous antigens by human dendritic cells
WO2001091738A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating amyotrophic lateral sclerosis
DE60107022T2 (en) 2000-07-24 2005-11-24 Health Research Inc. Method for the detection of prostate-specific membrane antigen in serum
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
AU2002239441A1 (en) 2000-11-01 2002-05-27 American Foundation For Biological Research, Inc. Methods and compositions for inducing cell-mediated immune responses
EP1390523B1 (en) 2000-11-20 2007-05-09 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
JP2005505242A (en) 2001-03-07 2005-02-24 マンカインド コーポレイション Anti-neovascular preparation for cancer
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
US20030007974A1 (en) 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7045335B2 (en) 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US7192586B2 (en) 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20040018519A1 (en) 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
WO2003057921A1 (en) 2001-12-26 2003-07-17 Sloan Kettering Institute For Cancer Research Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes
EP1472541B1 (en) 2002-01-10 2009-09-16 The Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
MXPA04007262A (en) 2002-01-28 2004-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen (psma).
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003073828A2 (en) 2002-03-01 2003-09-12 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
PT1545613E (en) 2002-07-31 2011-09-27 Seattle Genetics Inc Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2006028429A2 (en) 2002-08-05 2006-03-16 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
US20040180354A1 (en) 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
CA2514419A1 (en) 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US20050202020A1 (en) 2004-01-09 2005-09-15 Jeffrey Ross Diagnosing and treating cancer
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US8540968B2 (en) * 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
EP1610818A4 (en) 2004-03-03 2007-09-19 Millennium Pharm Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2005123129A2 (en) 2004-06-14 2005-12-29 Regents Of The University Of California Methods of redistributing apical target antigens to detect and treat cellular proliferative disease
WO2006013014A2 (en) 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2006076525A2 (en) 2005-01-14 2006-07-20 Cytogen Corporation Combination cancer therapy with anti-psma antibodies
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US20090297438A1 (en) 2005-02-18 2009-12-03 Haichun Huang Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
AU2006220621A1 (en) 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
AU2006235421A1 (en) 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-PSMA antibodies
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CA2612762C (en) 2005-06-20 2013-12-10 Psma Development Company, Llc Psma antibody-drug conjugates
US20100184699A1 (en) 2005-06-29 2010-07-22 Kyogo Itoh Peptide Derived From Prostate-Related Protein As Cancer Vaccine Candidate For Prostate Cancer Patient Who Is Positive For Hla-A3 Super-Type Allele Molecule
US7824659B2 (en) * 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
US20080279868A1 (en) 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
EP1948688A2 (en) 2005-11-14 2008-07-30 Psma Development Company, L.L.C. Compositions of and methods of using stabilized psma dimers
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DONOVAN G P ET AL: "ANTIBODY AND VACCINE THERAPIES TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, 24 March 2001 (2001-03-24), pages 818, XP001204629, ISSN: 0197-016X *
GONG M C ET AL: "Prostate-specific membrane antigen (PMSA)-specific monoclonal antibodies in the treatment of prostate and other cancers", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 18, no. 4, 1999, pages 483 - 490, XP002982445, ISSN: 0167-7659 *
HOLMES E H: "PSMA specific antibodies and their diagnostic and therapeutic use", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 3, March 2001 (2001-03-01), pages 511 - 519, XP002988381, ISSN: 1354-3784 *
LAPIDUS RENA G ET AL: "Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 45, no. 4, 1 December 2000 (2000-12-01), pages 350 - 354, XP009026666, ISSN: 0270-4137 *
LIU H ET AL: "MONOCLONAL ANTIBODIES TO THE EXTRACELLULAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALSO REACT WITH TUMOR VASCULAR ENDOTHELIUM", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 17, 1 September 1997 (1997-09-01), pages 3629 - 3634, XP001080132, ISSN: 0008-5472 *
SCHULKE N ET AL: "The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 22, 28 October 2003 (2003-10-28), pages 12590 - 12595, XP002323660, ISSN: 0027-8424 *
SMITH-JONES P M ET AL: "In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 18, 15 September 2000 (2000-09-15), pages 5237 - 5243, XP002327842, ISSN: 0008-5472 *
TINO WILLIAM T ET AL: "Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA)", HYBRIDOMA, vol. 19, no. 3, June 2000 (2000-06-01), pages 249 - 257, XP002397386, ISSN: 0272-457X *
TROYER J K ET AL: "DETECTION AND CHARACTERIZATION OF THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) IN TISSUE EXTRACTS AND BODY FLUIDS", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 62, 1 January 1995 (1995-01-01), pages 552 - 558, XP002944383, ISSN: 0020-7136, DOI: 10.1002/IJC.2910620511 *

Also Published As

Publication number Publication date
EP2363404B8 (en) 2016-12-07
CA2464239A1 (en) 2003-05-01
WO2003034903B1 (en) 2004-05-13
EP1448588A2 (en) 2004-08-25
EP2360169A3 (en) 2012-02-15
WO2003034903A3 (en) 2003-10-30
WO2003034903A2 (en) 2003-05-01
EP2360169B1 (en) 2015-10-14
US20040033229A1 (en) 2004-02-19
EP3184539A2 (en) 2017-06-28
ES2606537T3 (en) 2017-03-24
AU2002356844C1 (en) 2010-03-04
JP2009102443A (en) 2009-05-14
JP2005523683A (en) 2005-08-11
JP5703447B2 (en) 2015-04-22
EP2363404A3 (en) 2012-01-25
US8114965B2 (en) 2012-02-14
EP2363404B1 (en) 2016-09-07
EP3184539A3 (en) 2017-09-13
US7850971B2 (en) 2010-12-14
US20080286284A1 (en) 2008-11-20
EP2360169A2 (en) 2011-08-24
JP2012245010A (en) 2012-12-13
EP2363404A2 (en) 2011-09-07
AU2002356844B2 (en) 2009-11-12
JP5355839B2 (en) 2013-11-27
CA2464239C (en) 2016-07-12
ES2559002T3 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
EP1448588A4 (en) Psma antibodies and protein multimers
GB0130228D0 (en) Protein
EP1365022A4 (en) Adiponectin-associated protein
GB0108079D0 (en) Protein
GB0130557D0 (en) Proteins
GB0130720D0 (en) Proteins
EP1373306A4 (en) Cytoskeletion-associated proteins
GB0128161D0 (en) Receptor protein
GB0130721D0 (en) Protein
GB0106318D0 (en) Protein
GB0130560D0 (en) Proteins
AU2002326909A8 (en) Neurotransmission-associated proteins
GB0122813D0 (en) Protein
GB0114643D0 (en) Protein
GB0129661D0 (en) Protein
GB0120927D0 (en) Protein
GB0120719D0 (en) Protein
GB0125714D0 (en) Protein
GB0125717D0 (en) Protein
GB0126304D0 (en) Protein
GB0127019D0 (en) Protein
GB0127040D0 (en) Protein
GB0129631D0 (en) Protein
GB0120038D0 (en) Protein
GB0119447D0 (en) Protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040522

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069400

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20060921

17Q First examination report despatched

Effective date: 20071030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150224

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1069400

Country of ref document: HK